SK287928B6 - Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof - Google Patents

Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof Download PDF

Info

Publication number
SK287928B6
SK287928B6 SK220-2000A SK2202000A SK287928B6 SK 287928 B6 SK287928 B6 SK 287928B6 SK 2202000 A SK2202000 A SK 2202000A SK 287928 B6 SK287928 B6 SK 287928B6
Authority
SK
Slovakia
Prior art keywords
crystal
cyano
methyl
polymorphic
water
Prior art date
Application number
SK220-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK2202000A3 (en
Inventor
Koichi Matsumoto
Kenzo Watanabe
Toshiyuki Hiramatsu
Mitsutaka Kitamura
Original Assignee
Teijin Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15953825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287928(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Limited filed Critical Teijin Pharma Limited
Publication of SK2202000A3 publication Critical patent/SK2202000A3/sk
Publication of SK287928B6 publication Critical patent/SK287928B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK220-2000A 1998-06-19 1999-06-18 Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof SK287928B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17307998 1998-06-19
PCT/JP1999/003258 WO1999065885A1 (en) 1998-06-19 1999-06-18 Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
SK2202000A3 SK2202000A3 (en) 2000-11-07
SK287928B6 true SK287928B6 (sk) 2012-04-03

Family

ID=15953825

Family Applications (2)

Application Number Title Priority Date Filing Date
SK5040-2010A SK287946B6 (sk) 1998-06-19 1999-06-18 Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazolecarboxylic acid and a method of their preparation
SK220-2000A SK287928B6 (sk) 1998-06-19 1999-06-18 Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK5040-2010A SK287946B6 (sk) 1998-06-19 1999-06-18 Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazolecarboxylic acid and a method of their preparation

Country Status (38)

Country Link
US (1) US6225474B1 (cs)
EP (4) EP1020454B2 (cs)
JP (1) JP3547707B2 (cs)
KR (1) KR100511183B1 (cs)
CN (3) CN1275126A (cs)
AT (2) ATE449765T1 (cs)
AU (1) AU748026B2 (cs)
BE (1) BE2010C024I2 (cs)
BG (1) BG64734B1 (cs)
BR (1) BR9906539A (cs)
CA (2) CA2301863C (cs)
CY (3) CY1109720T1 (cs)
CZ (1) CZ298170B6 (cs)
DE (2) DE69941672D1 (cs)
DK (3) DK1956014T3 (cs)
ES (3) ES2371786T5 (cs)
FR (1) FR10C0022I2 (cs)
GT (1) GT199900216A (cs)
HR (2) HRP20120217B1 (cs)
HU (2) HU229405B1 (cs)
ID (1) ID25775A (cs)
IL (1) IL134594A (cs)
IN (1) IN191537B (cs)
IS (4) IS9020A (cs)
LT (1) LT1956014T (cs)
LU (1) LU91682I2 (cs)
NO (1) NO321308B1 (cs)
NZ (1) NZ503326A (cs)
PL (1) PL200710B1 (cs)
PT (3) PT1020454E (cs)
RU (1) RU2198169C3 (cs)
SI (3) SI1020454T2 (cs)
SK (2) SK287946B6 (cs)
TR (1) TR200000458T1 (cs)
TW (1) TWI248439B (cs)
UA (1) UA57611C2 (cs)
WO (1) WO1999065885A1 (cs)
ZA (1) ZA200000737B (cs)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1956014T3 (en) 1998-06-19 2019-04-15 Teijin Pharma Ltd Polymorphs of 2- (3-cyano-4-isobutyloxyphenyl) -4-methyl-5-thiazole carboxylic acid and process for their preparation
US20030109525A1 (en) * 2001-07-10 2003-06-12 Pharmacia & Upjohn Company Crystalline thiazine oxazolidinones
NZ531232A (en) 2001-08-15 2004-11-26 Pharmacia & Upjohn Inc Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
EP2272501B1 (en) 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
JP2003261548A (ja) * 2002-03-07 2003-09-19 Teijin Ltd ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
US7361676B2 (en) * 2002-03-28 2008-04-22 Teijin Limited Solid preparation containing single crystal form
US8841333B2 (en) * 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
CN100430055C (zh) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
WO2007148787A1 (ja) 2006-06-23 2007-12-27 Teijin Pharma Limited ２－（３－シアノ－４－イソブチルオキシフェニル）－４－メチル－５－チアゾールカルボン酸の結晶多形体の製造方法
CN101139325B (zh) * 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
CN101812035B (zh) * 2006-09-07 2012-03-21 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
KR20150024919A (ko) * 2006-11-13 2015-03-09 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
CN102093309B (zh) * 2006-12-07 2012-07-04 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN102093308B (zh) * 2006-12-07 2012-08-29 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN1970547B (zh) * 2006-12-07 2011-04-06 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
EP2120956A4 (en) * 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
CN101412700B (zh) * 2007-10-19 2011-06-08 上海医药工业研究院 非布司他的晶型及其制备方法
CN101386605B (zh) * 2008-10-23 2010-09-08 中国科学院上海药物研究所 非布司他新型晶体及其制备方法
CN101759656B (zh) * 2008-12-12 2013-04-03 重庆医药工业研究院有限责任公司 非布司他新晶型及其制备方法
CN101768150B (zh) * 2009-01-05 2014-08-06 常州市第四制药厂有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CN101891702B (zh) * 2009-05-22 2012-07-04 重庆圣华曦药业股份有限公司 非布司他的晶体、制备方法及在药物中的应用
PL2398784T3 (pl) 2009-06-10 2013-07-31 Teva Pharma Postacie krystaliczne febuksostatu
JP5519201B2 (ja) * 2009-07-15 2014-06-11 光孝 北村 ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
WO2011007895A1 (ja) 2009-07-15 2011-01-20 帝人ファーマ株式会社 貧溶媒添加法による２－（３－シアノ－４－イソブチルオキシフェニル）－４－メチル－５－チアゾールカルボン酸の結晶多形体の製造方法
CN103936689B (zh) * 2009-07-17 2016-08-17 北京利乐生制药科技有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法
WO2011080651A2 (en) 2009-12-31 2011-07-07 Ranbaxy Laboratories Limited Polymorphic forms of febuxostat
WO2011101867A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
WO2011107911A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid
CN101824005B (zh) * 2010-04-27 2012-06-27 上海凯米侬医药科技有限公司 一种非布索坦的晶型q及其制备方法
WO2011134101A1 (zh) * 2010-04-27 2011-11-03 上海凯米侬医药科技有限公司 一种非布索坦的新晶型n及其制备方法
WO2011139886A2 (en) * 2010-04-29 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
EP2399911B1 (en) 2010-06-25 2015-08-19 Sandoz Ag Polymorphs of Febuxostat
TW201217347A (en) * 2010-07-13 2012-05-01 Interquim Sa Process for preparing the crystalline form a of febuxostat
WO2012020272A2 (en) 2010-08-13 2012-02-16 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság New salts, polymorphs and solvates of a pharmaceutical active ingredient
CN103298466B (zh) 2010-09-10 2015-11-25 武田制药美国有限公司 茶碱和非布索坦的联合治疗方法
CA2811912A1 (en) * 2010-09-24 2012-03-29 Hetero Research Foundation Novel polymorphs of febuxostat
CN102442971B (zh) * 2010-10-13 2014-06-18 欣凯医药化工中间体（上海）有限公司 非布司他的晶型及其制备方法
WO2012048861A1 (en) * 2010-10-14 2012-04-19 Gador S.A. A novel febuxostat crystalline form and the process for the preparation thereof
US20130225830A1 (en) * 2010-10-28 2013-08-29 Mapi Pharma Limited Polymorphs of febuxostat
TWI520732B (zh) * 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
CN102127033A (zh) * 2011-01-21 2011-07-20 北京虹湾医药技术有限公司 非布索坦晶型及其工业化制备方法
EP2502920A1 (en) 2011-03-25 2012-09-26 Sandoz Ag Crystallization process of Febuxostat from A
WO2012131590A1 (en) 2011-03-31 2012-10-04 Sandoz Ag An improved process for preparation of febuxostat and its polymorphic crystalline form c thereof
AU2012241378A1 (en) 2011-04-15 2013-10-31 Sun Pharmaceutical Industries Limited Febuxostat solid dispersion
WO2012153313A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Pharmaceutical composition of febuxostat
EP2718272A2 (en) * 2011-06-06 2014-04-16 Hetero Research Foundation Process for febuxostat
WO2012172461A1 (en) 2011-06-13 2012-12-20 Ranbaxy Laboratories Limited Pharmaceutical compositions of febuxostat
AU2012342011A1 (en) 2011-11-15 2014-06-05 Mylan Laboratories Ltd Process for the preparation of Febuxostat polymorphs
WO2013088449A1 (en) 2011-12-16 2013-06-20 Natco Pharma Limited Stable crystal form of febuxostat and process for the preparation thereof
EP2925306A1 (en) 2012-07-12 2015-10-07 Alembic Pharmaceuticals Limited Pharmaceutical composition of febuxostat
EP2692342A1 (en) 2012-07-30 2014-02-05 Interquim, S.A. Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets
WO2014057461A1 (en) 2012-10-11 2014-04-17 Ranbaxy Laboratories Limited Process for the preparation of crystalline form g of febuxostat
CN103936688A (zh) * 2013-01-21 2014-07-23 上海华拓医药科技发展股份有限公司 2-(3-氰基-4-(2-甲基丙氧基)苯基)-4-甲基-5-噻唑甲酸a晶的制备方法
MX363191B (es) * 2013-03-29 2019-03-14 Teijin Pharma Ltd Derivado de pirazol.
CN103396378B (zh) * 2013-07-29 2015-06-10 杭州朱养心药业有限公司 非布司他结晶
CN103588724B (zh) * 2013-09-10 2015-05-20 杭州华东医药集团新药研究院有限公司 一种非布司他晶型a及其制备方法
RU2016119523A (ru) * 2013-10-22 2017-11-28 Ниппон Кемифар Ко., Лтд. Мелкие кристаллы 2-[3-циано-4-(2-метилпропокси)фенил]-4-метилтиазол-5-карбоновой кислоты, продукт их тонкого измельчения и содержащие их твердые препараты
EP2881116A1 (en) 2013-12-05 2015-06-10 Ranbaxy Laboratories Limited Febuxostat composition
EP2902016A1 (en) 2014-01-30 2015-08-05 Alfred E. Tiefenbacher (GmbH & Co. KG) Febuxostat tablet
CN103739568B (zh) * 2014-02-07 2015-09-16 浙江普洛康裕制药有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法
RS58315B1 (sr) 2014-07-30 2019-03-29 Teijin Pharma Ltd Derivat azol benzena i njegov kristal
EP3002006A1 (en) 2014-10-01 2016-04-06 Bluepharma - Industria Farmacêutica, S.A. Pharmaceutical composition capable for the incorporation Febuxostat in the crystalline modifications F10, II, G and A
CZ27857U1 (cs) 2014-12-12 2015-02-23 Zentiva, K.S. Formulace obsahující tuhý roztok febuxostatu
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
JP7164926B2 (ja) * 2015-04-22 2022-11-02 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の結晶、その製造方法、及びそれらの利用
EP3153158A1 (de) 2015-10-09 2017-04-12 Stada Arzneimittel Ag Orale febuxostat-tablette
CN107540630A (zh) * 2016-06-29 2018-01-05 康普药业股份有限公司 一种非布司他化合物及制备方法
GR1009119B (el) 2016-06-30 2017-09-18 "Φαρματεν Α.Β.Ε.Ε." Φαρμακευτικο σκευασμα περιεχον ενα μη πουρινικο επιλεκτικο αναστολεα της οξειδασης της ξανθινης και μεθοδος παρασκευης αυτου
KR20180013563A (ko) * 2016-07-29 2018-02-07 한미정밀화학주식회사 고순도 결정형 페북소스타트의 개선된 제조 방법
CN106565627B (zh) * 2016-10-10 2020-01-10 扬子江药业集团有限公司 一种非布司他药用晶型的制备方法
GR1009659B (el) 2018-09-07 2019-11-28 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα συμπλοκο αλατος της φεβουξοστατης με οξειδιο του μαγνησιου και μεθοδος για την παρασκευη αυτου
US11498893B2 (en) 2018-09-28 2022-11-15 Kaneka Corporation Production method for crystal of reduced coenzyme Q10 having excellent stability
CN112390766B (zh) * 2019-08-13 2022-09-06 浙江天宇药业股份有限公司 一种非布司他a晶型的制备方法
CN111004191A (zh) * 2019-10-24 2020-04-14 武汉光谷亚太医药研究院有限公司 一种大粒径非布司他a晶的制备方法
JP7506475B2 (ja) * 2019-12-26 2024-06-26 東和薬品株式会社 フェブキソスタット製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8506572D0 (en) † 1985-03-14 1985-04-17 Appointrose Ltd Fire-resistant enclosures
ATE72244T1 (de) 1986-03-21 1992-02-15 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
SU1417437A1 (ru) * 1986-12-30 1994-01-30 Институт органической и физической химии им.А.Е.Арбузова Способ получения 4-тиазолкарбоновой кислоты
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
KR100221041B1 (ko) 1990-11-30 1999-09-15 야스이 쇼사꾸 2-아릴티아졸 유도체 및 그의 약제학적 조성물
JP2706037B2 (ja) * 1993-04-13 1998-01-28 帝人株式会社 シアノ化合物およびその製造方法
JP3202607B2 (ja) 1996-08-01 2001-08-27 帝人株式会社 ２−（４−アルコキシ−３−シアノフェニル）チアゾール誘導体の製造法
DK1956014T3 (en) 1998-06-19 2019-04-15 Teijin Pharma Ltd Polymorphs of 2- (3-cyano-4-isobutyloxyphenyl) -4-methyl-5-thiazole carboxylic acid and process for their preparation
US7361676B2 (en) 2002-03-28 2008-04-22 Teijin Limited Solid preparation containing single crystal form

Also Published As

Publication number Publication date
IS2886B (is) 2014-07-15
PT1956015E (pt) 2011-11-02
EP1956015A3 (en) 2008-09-17
DK1020454T3 (da) 2010-01-04
AU4289299A (en) 2000-01-05
CY1111841T1 (el) 2015-10-07
SK2202000A3 (en) 2000-11-07
AU748026B2 (en) 2002-05-30
PL338780A1 (en) 2000-11-20
EP1956014A3 (en) 2008-08-20
CZ2000582A3 (cs) 2000-07-12
IL134594A (en) 2004-12-15
CA2566652A1 (en) 1999-12-23
HRP20000092C1 (en) 2012-04-30
DK1956015T4 (en) 2019-02-11
NO20000789D0 (no) 2000-02-17
CA2566652C (en) 2008-10-21
HRP20120217B1 (hr) 2019-04-05
DE69941672D1 (de) 2010-01-07
EP1956015A2 (en) 2008-08-13
PT1020454E (pt) 2009-12-21
IL134594A0 (en) 2001-04-30
EP1956014B1 (en) 2019-01-16
KR20010023061A (ko) 2001-03-26
HRPK20000092B1 (hr) 2001-10-31
RU2198169C3 (ru) 2017-07-20
CN1275126A (zh) 2000-11-29
HUP0004325A2 (hu) 2001-10-28
HUP0004325A3 (en) 2001-12-28
SI1956015T1 (sl) 2011-10-28
IN191537B (cs) 2003-12-06
CN102020617A (zh) 2011-04-20
IS5377A (is) 2000-02-17
DE122010000013I1 (de) 2010-07-08
WO1999065885A1 (en) 1999-12-23
HU230799B1 (hu) 2018-06-28
EP1020454B2 (en) 2013-01-23
NO321308B1 (no) 2006-04-24
CY2010006I1 (el) 2012-01-25
CN102020617B (zh) 2019-04-23
ES2371786T5 (es) 2019-04-22
EP1956014A2 (en) 2008-08-13
BG104159A (en) 2000-08-31
LU91682I9 (cs) 2019-01-09
ATE449765T1 (de) 2009-12-15
EP1020454B1 (en) 2009-11-25
CN102659712A (zh) 2012-09-12
ES2371786T3 (es) 2012-01-10
NZ503326A (en) 2002-02-01
RU2198169C2 (ru) 2003-02-10
PT1956014T (pt) 2019-04-24
SI1020454T1 (sl) 2010-02-26
DK1956015T3 (da) 2011-09-26
HK1029788A1 (en) 2001-04-12
EP2404910A3 (en) 2014-10-29
KR100511183B1 (ko) 2005-08-30
DK1020454T4 (da) 2013-11-25
CZ298170B6 (cs) 2007-07-11
SI1956015T2 (sl) 2018-12-31
IS9022A (is) 2013-01-25
ES2718467T3 (es) 2019-07-02
LT1956014T (lt) 2019-03-25
TR200000458T1 (tr) 2000-10-23
DK1956014T3 (en) 2019-04-15
HU229405B1 (en) 2013-12-30
IS9020A (is) 2013-01-25
CY1109720T1 (el) 2012-01-25
EP1020454A4 (en) 2002-05-15
FR10C0022I2 (fr) 2013-08-16
SK287946B6 (sk) 2012-06-04
BG64734B1 (bg) 2006-01-31
ZA200000737B (en) 2000-09-08
TWI248439B (en) 2006-02-01
CA2301863A1 (en) 1999-12-23
EP1956015B2 (en) 2018-11-14
ES2336287T5 (es) 2013-04-02
EP1020454A1 (en) 2000-07-19
IS3002B (is) 2018-09-15
SI1956014T1 (sl) 2019-02-28
CY2010006I2 (el) 2012-01-25
HRP20120217A2 (hr) 2012-05-31
UA57611C2 (uk) 2003-06-16
EP1956015B1 (en) 2011-08-31
IS9021A (is) 2013-01-25
ES2336287T3 (es) 2010-04-09
EP2404910A2 (en) 2012-01-11
GT199900216A (es) 2001-06-08
CA2301863C (en) 2009-01-27
ID25775A (id) 2000-11-02
JP3547707B2 (ja) 2004-07-28
ATE522512T2 (de) 2011-09-15
US6225474B1 (en) 2001-05-01
FR10C0022I1 (cs) 2010-05-14
PL200710B1 (pl) 2009-01-30
NO20000789L (no) 2000-02-17
BE2010C024I2 (en) 2018-08-24
LU91682I2 (fr) 2010-06-22
HK1118293A1 (en) 2009-02-06
BR9906539A (pt) 2000-08-15
SI1020454T2 (sl) 2013-03-29
HRP20000092A2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
SK287928B6 (sk) Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
US4894459A (en) Process for the preparation of morphologically homogeneous forms of thiazole derivatives
CN107531728B (zh) 可用于治疗阿尔茨海默氏病的四氢呋喃稠合的氨基氢噻嗪衍生物
HK1029788B (en) Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
HK1118293B (en) Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
HK1160844A (en) Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
MXPA00001399A (en) Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: TEIJIN PHARMA LIMITED, TOKYO, JP

Free format text: FORMER OWNER: TEIJIN LIMITED, CHUO-KU, OSAKA-SHI, OSAKA, JP

Effective date: 20090121

SPCF Filing of an spc

Free format text: PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001 - EU/1/08/447/008 20080421

Spc suppl protection certif: 5016-2012

Filing date: 20120717

PC4A Assignment and transfer of rights

Owner name: TEIJIN LIMITED, CHUO-KU, OSAKA-SHI, OSAKA, JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, TOKYO, JP

Effective date: 20120801

SPCG Grant of an spc

Free format text: PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001 - EU/1/08/447/008 20080421

Spc suppl protection certif: 157 5016-2012

Filing date: 20120717

Extension date: 20230421

MK4A Patent expired

Expiry date: 20190618